SLP-2: a potential new target for improving mitochondrial function in Parkinson's disease
Alessandra Zanon
Andrew A. Hicks
Peter P. Pramstaller
Irene Pichler
摘要：Parkinson's disease (PD) is a progressive neurodegenerative disease, which is generally considered a multifactorial disorder that arises owing to a combination of genes and environmental factors. While most cases are idiopathic, in about 10% of the patients a genetic cause can be detected, ascribable to mutations in more than a dozen genes. PD is characterized clinically by tremor, rigidity, reduced mo-tor activity (bradykinesia), and postural instability and pathological-ly by loss of dopaminergic (DA) neurons in the substantia nigra pars compacta, loss of DA innervation in the striatum, and the presence of α-synuclein positive aggregates in the form of Lewy bodies. The symptomatic treatment of PD with levodopa, which aims at replac-ing dopamine, remains the gold standard, and no neuroprotective or disease-modifying therapy is available. During treatment, the disease continues to progress, and long-term use of levodopa has import-ant limitations including motor complications termed dyskinesias.Therefore, a pharmacological therapy able to prevent or halt the neu-rodegenerative process is urgently required.
机标关键词：pharmacological therapyenvironmental factorssubstantia nigraform of
论文发表日期：2017-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 1435-1436 )